BIOHEART-B (02185): IBERIS® RDN System Completes Market Access and First Commercial Procedure in Switzerland

Stock News

Oct 23

According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first commercial procedure for the Iberis® Radial Denervation System (IBERIS® RDN System) in Switzerland. This procedure was conducted at the University Hospital of Basel, with no reported complications or adverse events. The case received joint support from Borsham International Group Ltd. (Borsham) and Antong. Antong and Borsham have formed a strategic partnership for the commercialization of the Iberis® RDN System, covering several regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of this announcement, the Iberis® RDN System is the only renal denervation (RDN) product globally authorized for use via the transradial approach (TRA) and transfemoral approach (TFA). The TRA makes RDN safer, more effective, and more cost-efficient. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong acquired the CE mark for the Iberis® RDN System in Europe in 2016.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113038841"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113038841\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113038841?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113038841","market":"us","top_or_hot":-1,"title":"BIOHEART-B (02185): IBERIS® RDN System Completes Market Access and First Commercial Procedure in Switzerland","media":"Stock News","content":"<p>According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first commercial procedure for the Iberis® Radial Denervation System (IBERIS® RDN System) in Switzerland. This procedure was conducted at the University Hospital of Basel, with no reported complications or adverse events. The case received joint support from Borsham International Group Ltd. (Borsham) and Antong. Antong and Borsham have formed a strategic partnership for the commercialization of the Iberis® RDN System, covering several regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of this announcement, the Iberis® RDN System is the only renal denervation (RDN) product globally authorized for use via the transradial approach (TRA) and transfemoral approach (TFA). The TRA makes RDN safer, more effective, and more cost-efficient. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong acquired the CE mark for the Iberis® RDN System in Europe in 2016.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B (02185): IBERIS® RDN System Completes Market Access and First Commercial Procedure in Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B (02185): IBERIS® RDN System Completes Market Access and First Commercial Procedure in Switzerland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-23 19:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first commercial procedure for the Iberis® Radial Denervation System (IBERIS® RDN System) in Switzerland. This procedure was conducted at the University Hospital of Basel, with no reported complications or adverse events. The case received joint support from Borsham International Group Ltd. (Borsham) and Antong. Antong and Borsham have formed a strategic partnership for the commercialization of the Iberis® RDN System, covering several regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of this announcement, the Iberis® RDN System is the only renal denervation (RDN) product globally authorized for use via the transradial approach (TRA) and transfemoral approach (TFA). The TRA makes RDN safer, more effective, and more cost-efficient. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong acquired the CE mark for the Iberis® RDN System in Europe in 2016.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154245756.USD","symbol_name":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","start_time":0,"source_url":"","article_id":"1113038841","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113038841","pubTimestamp":1761220335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","RDN":"Radian Group Inc","02185":"百心安-B","BK4229":"商业和住宅抵押贷款融资","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK1100":"医疗保健设备","BK4195":"互助储蓄与抵押信贷金融服务"},"translate_title":"BIOHEART-B(02185)：伊比利亚®RDN系统在瑞士完成市场准入和首个商业程序","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1,"RDN":1},"content_text":"According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first commercial procedure for the Iberis® Radial Denervation System (IBERIS® RDN System) in Switzerland. This procedure was conducted at the University Hospital of Basel, with no reported complications or adverse events. The case received joint support from Borsham International Group Ltd. (Borsham) and Antong. Antong and Borsham have formed a strategic partnership for the commercialization of the Iberis® RDN System, covering several regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of this announcement, the Iberis® RDN System is the only renal denervation (RDN) product globally authorized for use via the transradial approach (TRA) and transfemoral approach (TFA). The TRA makes RDN safer, more effective, and more cost-efficient. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong acquired the CE mark for the Iberis® RDN System in Europe in 2016.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}